Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.
Thromb Res. 2019 Jan;173:79-84. doi: 10.1016/j.thromres.2018.11.017. Epub 2018 Nov 16.
Standard prophylaxis dosing based on bodyweight may result in over- or under-dosing due to interpatient variability. Adopting individual pharmacokinetic (PK) based tailoring may improve adherence to treatment guideline, and consequently clinical outcomes. Here we report clinical observations performed across the adoption of individual PK based tailoring in a single center in Japan.
An individual PK study on sparse samples was modeled on myPKFiT or WAPPS-Hemo, depending on concentrate, and used to optimize treatment regimens. Adherence to prophylaxis and bleeding rate were calculated from patient diaries. Radiological joint scores were used to assess arthropathy, and SPSS to perform all the analyses.
Thirty-nine patients underwent PK profiling, and 20 required and accepted a modification of their treatment (8 increases in dose, 5 reductions in frequency, 5 switches to extended half-life (EHL)). Adherence to prophylaxis remained the same in those increasing the dose, whilst increased in all the other groups. Annualized bleeding rate (ABR) and annualized joint bleeding rate (AjBR) decreased in all the groups but reached statistical significance only in those switched to EHL and showed a larger reduction in those patients without baseline arthropathy. Longer time spent above a 1% or 5% threshold was associated with a decrease in the ABR/AjBR.
Our study results suggest that PopPK based tailoring supported changing treatment regimen in nearly half of the patients, and may have contributed to an improvement in the adherence and a reduction in the ABR/AjBR.
基于体重的标准预防剂量可能会因个体间变异性而导致剂量过高或过低。采用个体药代动力学(PK)定制化可能会提高治疗指南的依从性,从而改善临床结果。在此,我们报告了在日本的一家中心采用个体 PK 定制化的临床观察结果。
根据浓缩物,使用 myPKFiT 或 WAPPS-Hemo 对稀疏样本进行个体 PK 研究建模,并用于优化治疗方案。根据患者日记计算预防用药的依从性和出血率。关节放射学评分用于评估关节病,SPSS 用于进行所有分析。
39 名患者进行了 PK 分析,其中 20 名需要并接受了治疗方案的修改(8 名增加剂量,5 名减少频率,5 名改为延长半衰期(EHL))。增加剂量的患者预防用药的依从性保持不变,而其他组则增加了。所有组的年化出血率(ABR)和年化关节出血率(AjBR)均降低,但仅在改为 EHL 的组中达到统计学意义,且在无基线关节病的患者中降低幅度更大。在高于 1%或 5%阈值的时间延长与 ABR/AjBR 的降低相关。
我们的研究结果表明,基于群体 PK 的定制化支持近一半患者改变治疗方案,可能有助于提高依从性和降低 ABR/AjBR。